Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
37
SWTX Quote, Financials, Valuation and Earnings
Last price:
$36.80
Seasonality move
:
4.38%
Day range:
$36.59 - $37.60
52-week range:
$28.21 - $53.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.53x
P/B ratio:
5.14x
Volume:
286.2K
Avg. volume:
1.4M
1-year change:
3.31%
Market cap:
$2.7B
Revenue:
$5.4M
EPS (TTM):
-$3.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$55.1M | -$0.76 | 948.89% | -55.59% | $68.13 |
|
BPMC
Blueprint Medicines
|
$127.5M | -$0.96 | 101.97% | -63.42% | $125.58 |
|
EWTX
Edgewise Therapeutics
|
-- | -$0.37 | -- | -15.68% | $49.43 |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
PTCT
PTC Therapeutics
|
$171.8M | -$1.66 | -37.97% | -75.73% | -- |
|
VRTX
Vertex Pharmaceuticals
|
$2.7B | $4.13 | 10.63% | 10.37% | $493.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$36.81 | $68.13 | $2.7B | -- | $0.00 | 0% | 19.53x |
|
BPMC
Blueprint Medicines
|
$90.46 | $125.58 | $5.7B | -- | $0.00 | 0% | 13.06x |
|
EWTX
Edgewise Therapeutics
|
$29.62 | $49.43 | $2.8B | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.54 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
PTCT
PTC Therapeutics
|
$45.35 | -- | $3.5B | -- | $0.00 | 0% | 3.85x |
|
VRTX
Vertex Pharmaceuticals
|
$408.18 | $493.61 | $105.1B | 25.59x | $0.00 | 0% | 10.00x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
-- | 2.409 | -- | 5.80x |
|
BPMC
Blueprint Medicines
|
55.25% | 2.789 | 6.59% | 3.10x |
|
EWTX
Edgewise Therapeutics
|
-- | -0.011 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
PTCT
PTC Therapeutics
|
-37.06% | 0.081 | 9.99% | 1.99x |
|
VRTX
Vertex Pharmaceuticals
|
-- | 0.893 | -- | 2.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$46M | -$57.9M | -51.38% | -51.38% | -117.52% | -$27.2M |
|
BPMC
Blueprint Medicines
|
$126.3M | -$49M | -23.14% | -50.13% | -29.05% | -$13.7M |
|
EWTX
Edgewise Therapeutics
|
-- | -$40.4M | -- | -- | -- | -$27.9M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTCT
PTC Therapeutics
|
$185.9M | -$52M | -425.51% | -- | -28.65% | -$87.8M |
|
VRTX
Vertex Pharmaceuticals
|
$2.4B | $1.1B | -2.89% | -2.89% | 44.43% | $1.3B |
SpringWorks Therapeutics vs. Competitors
-
Which has Higher Returns SWTX or BPMC?
Blueprint Medicines has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -43.9%. SpringWorks Therapeutics's return on equity of -51.38% beat Blueprint Medicines's return on equity of -50.13%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M BPMCBlueprint Medicines98.49% -$0.89 $699.7M -
What do Analysts Say About SWTX or BPMC?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand Blueprint Medicines has an analysts' consensus of $125.58 which suggests that it could grow by 38.82%. Given that SpringWorks Therapeutics has higher upside potential than Blueprint Medicines, analysts believe SpringWorks Therapeutics is more attractive than Blueprint Medicines.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 BPMCBlueprint Medicines9 5 1 -
Is SWTX or BPMC More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.419%.
-
Which is a Better Dividend Stock SWTX or BPMC?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or BPMC?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Blueprint Medicines quarterly revenues of $128.2M. SpringWorks Therapeutics's net income of -$53.5M is higher than Blueprint Medicines's net income of -$56.3M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 13.06x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M BPMCBlueprint Medicines13.06x -- $128.2M -$56.3M
-
Which has Higher Returns SWTX or EWTX?
Edgewise Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -51.38% beat Edgewise Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M EWTXEdgewise Therapeutics-- -$0.36 -- -
What do Analysts Say About SWTX or EWTX?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.43 which suggests that it could grow by 66.88%. Given that SpringWorks Therapeutics has higher upside potential than Edgewise Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Edgewise Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 EWTXEdgewise Therapeutics4 0 0 -
Is SWTX or EWTX More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SWTX or EWTX?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or EWTX?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than Edgewise Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$53.5M is lower than Edgewise Therapeutics's net income of -$34.1M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M EWTXEdgewise Therapeutics-- -- -- -$34.1M
-
Which has Higher Returns SWTX or NBY?
NovaBay Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -49.65%. SpringWorks Therapeutics's return on equity of -51.38% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About SWTX or NBY?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than SpringWorks Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than SpringWorks Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is SWTX or NBY More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock SWTX or NBY?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or NBY?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. SpringWorks Therapeutics's net income of -$53.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns SWTX or PTCT?
PTC Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -54.2%. SpringWorks Therapeutics's return on equity of -51.38% beat PTC Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M PTCTPTC Therapeutics94.49% -$1.39 -$769.2M -
What do Analysts Say About SWTX or PTCT?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 29.47%. Given that SpringWorks Therapeutics has higher upside potential than PTC Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 PTCTPTC Therapeutics6 3 1 -
Is SWTX or PTCT More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.
-
Which is a Better Dividend Stock SWTX or PTCT?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or PTCT?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. SpringWorks Therapeutics's net income of -$53.5M is higher than PTC Therapeutics's net income of -$106.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 3.85x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M PTCTPTC Therapeutics3.85x -- $196.8M -$106.7M
-
Which has Higher Returns SWTX or VRTX?
Vertex Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of 37.71%. SpringWorks Therapeutics's return on equity of -51.38% beat Vertex Pharmaceuticals's return on equity of -2.89%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics93.22% -$0.72 $532.6M VRTXVertex Pharmaceuticals85.84% $4.01 $15.6B -
What do Analysts Say About SWTX or VRTX?
SpringWorks Therapeutics has a consensus price target of $68.13, signalling upside risk potential of 85.07%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that SpringWorks Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than Vertex Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 VRTXVertex Pharmaceuticals17 11 2 -
Is SWTX or VRTX More Risky?
SpringWorks Therapeutics has a beta of 0.862, which suggesting that the stock is 13.8% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.
-
Which is a Better Dividend Stock SWTX or VRTX?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or VRTX?
SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. SpringWorks Therapeutics's net income of -$53.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.53x versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics19.53x -- $49.3M -$53.5M VRTXVertex Pharmaceuticals10.00x 25.59x $2.8B $1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
